Tomino Y, Sakai H, Hanzawa S, Ohno J, Kitajima T, Sakai O
Jpn J Med. 1987 May;26(2):162-6. doi: 10.2169/internalmedicine1962.26.162.
A multi-center study on the clinical effect of danazol in patients with IgA nephropathy is described. Two different doses of oral administration, including 200 mg or 300 mg per day, were employed in the present study. Urinalysis and measurements of complement components, i.e. C3 and C4, were performed before, and in the eighth and 20th week after the administration of danazol. It was demonstrated that 200 or 300 mg of danazol administration was effective in reducing the amount of proteinuria and in increasing the levels of serum complement components in the patients. It is concluded that the administration of danazol may be useful for treatment of patients with IgA nephropathy.
本文描述了一项关于达那唑对IgA肾病患者临床疗效的多中心研究。本研究采用两种不同剂量的口服给药方式，即每日200毫克或300毫克。在服用达那唑之前以及服药后的第八周和第二十周进行了尿液分析和补体成分（即C3和C4）的测量。结果表明，服用200毫克或300毫克达那唑可有效减少患者蛋白尿的量，并提高血清补体成分水平。得出结论，达那唑给药可能对治疗IgA肾病患者有用。
